Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Akarna’s lead program is a potential best-in-class therapeutic for the treatment of non-alcoholic steatohepatitis (NASH). On August 26, 2016 Akarna was acquired by Allergan for an USD 50m upfront cash payment and success-based development, approval and sales milestone payments.
Location: United Kingdom, England, South Hams
Total raised: $15M
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Third Poin... | thirdpoint... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.02.2016 | Series B | $15M | Forbion |
Mentions in press and media 4
| Date | Title | Description |
| 21.09.2016 | Allergan Acquires Akarna Therapeutics, for $50M | Allergan plc., (NYSE: AGN), acquired Akarna Therapeutics Ltd., a Cambridge, UK-based biopharmaceutical company, for an upfront cash payment of $50m. The deal also included success-based development, regulatory and sales milestones. Under th... |
| 16.02.2016 | Akarna Therapeutics Gets $15M | San Diego- and Cambridge, England-based Akarna Therapeutics Ltd. announced this morning that it has raised $15M in a Series B funding round. The biopharmaceutials company, whch is working on treatments for non-alcoholic steatohepatitis (NAS... |
| 16.02.2016 | Akarna Therapeutics Closes $15M Series B Financing | Akarna Therapeutics Ltd., a Cambridge, UK- and Encinitas, California-based biopharmaceutical company, closed a $15m Series B financing. New investor Forbion Capital Partners joined existing investors New Science Ventures and Third Point Ven... |
| 16.02.2016 | Akarna Therapeutics Lands $15M | SAN DIEGO, CA, Akarna Therapeutics, a privately held biopharmaceutical company, today announced the closing of a $15 million Series B preferred stock financing. >> Click here for more funding data on Akarna Therapeutics >> T... |